IMFINZI 50 mg/mL concentrate for solution for infusion., Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets
D9311L00001
Approved small_molecule active
Quick answer
IMFINZI 50 mg/mL concentrate for solution for infusion., Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets for Advanced or recurrent endometrial cancer is a Approved program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Advanced or recurrent endometrial cancer
- Phase
- Approved
- Modality
- small_molecule
- Status
- active